WFU

2019年7月4日 星期四

100篇您可能會想知道的高劑量維他命C與癌症相關醫學文獻

以下文獻集中在針對高劑量維他命C注射療法於癌症的領域文章包括案例討論臨床trial回溯性大規模研究review article(文獻綜論)等等。

結論便是已有大量的醫學文獻佐證在適宜劑量的高劑量維他命C是安全極少副作用(幾乎可說是無)的極佳癌症輔助療法,對於提高病患存活率、改善化療或放療的副作用、提高病患整體精神、改善食慾、促進不易癒合的傷口、改善疼痛與慢性發炎等都有很多正面的支持證據。


醫學文獻所提到高劑量維他命C注射療法具有正面意義的癌症包括:
 乳癌、卵巢癌、肺癌、子宮頸癌、大腸直腸癌、胰臟癌、膀胱癌、黑色素細胞癌、頭頸部癌症、腦癌、血癌、淋巴癌……您可以任意地將您所想知道的癌症醫學英文名+high dose vit C去搜尋,相信可以找到許多您感興趣的正面支持文獻。

除了癌症治療以外,高劑量維他命C注射對許多發炎狀態、難癒合傷口、中毒、逆轉氧化狀態、甚至憂鬱情緒等都有很優異的表現,若您對高劑量維他命C療法想了解更多,歡迎到鴻林診所找專業醫師諮詢。

門診時間


Copyrignt©汪郁榮醫師,保留所有權利



REFERENCES

1. Cameron E, Campbell A. The orthomolecular treatment of cancer. ii. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974;9:285–315. doi: 10.1016/0009-2797(74)90019-2. [PubMed] [CrossRef] [Google Scholar]

2. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978;75:4538–42. doi: 10.1073/pnas.75.9.4538. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24:269–76. [PubMed] [Google Scholar]

4. Hoffer LJ, Levine M, Assouline S, et al. Phase i clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19:1969–74. doi: 10.1093/annonc/mdn377. [Erratum in: Ann Oncol 2008;19:2095] [PubMed] [CrossRef] [Google Scholar]

5. Monti DA, Mitchell E, Bazzan AJ, et al. Phase i evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7:e29794. doi: 10.1371/journal.pone.0029794. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Welsh JL, Wagner BA, van’t Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (pacman): results from a phase i clinical trial. Cancer Chemother Pharmacol. 2013;71:765–75. doi: 10.1007/s00280-013-2070-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Stephenson CM, Levin RD, Spector T, Lis CG. Phase i clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72:139–46. doi: 10.1007/s00280-013-2179-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6:222ra18. doi: 10.1126/scitranslmed.3007154. [PubMed] [CrossRef] [Google Scholar]

9. Hoffman FA. Micronutrient requirements of cancer patients. Cancer. 1985;55(suppl):295–300. doi: 10.1002/1097-0142(19850101)55:1+<295::AID-CNCR2820551315>3.0.CO;2-X. [PubMed] [CrossRef] [Google Scholar]

10. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med. 2005;19:17–20. doi: 10.1191/0269216305pm970oa. [PubMed] [CrossRef] [Google Scholar]

11. Mahdavi R, Faramarzi E, Seyedrezazadeh E, Mohammad-Zadeh M, Pourmoghaddam M. Evaluation of oxidative stress, antioxidant status and serum vitamin C levels in cancer patients. Biol Trace Elem Res. 2009;130:1–6. doi: 10.1007/s12011-008-8309-2. [PubMed] [CrossRef] [Google Scholar]

12. Ramaswamy G, Krishnamoorthy L. Serum carotene, vitamin A, and vitamin C levels in breast cancer and cancer of the uterine cervix. Nutr Cancer. 1996;25:173–7. doi: 10.1080/01635589609514439. [PubMed] [CrossRef] [Google Scholar]

13. Torun M, Yardim S, Gönenç A, Sargin H, Menevşe A, Símşek B. Serum beta-carotene, vitamin E, vitamin C and malondi-aldehyde levels in several types of cancer. J Clin Pharm Ther. 1995;20:259–63. doi: 10.1111/j.1365-2710.1995.tb00660.x. [PubMed] [CrossRef] [Google Scholar]

14. Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. BMJ. 1998;316:1661–2. doi: 10.1136/bmj.316.7145.1661. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Mikirova N, Casciari J, Riordan N, Hunninghake R. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med. 2013;11:191. doi: 10.1186/1479-5876-11-191. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Alexandrescu DT, Dasanu CA, Kauffman CL. Acute scurvy during treatment with interleukin-2. Clin Exp Dermatol. 2009;34:811–14. doi: 10.1111/j.1365-2230.2008.03052.x. [PubMed] [CrossRef] [Google Scholar]

17. Bodansky O, Wroblewski F, Markardt B. Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer. 1952;5:678–84. doi: 10.1002/1097-0142(195207)5:4<678::AID-CNCR2820050404>3.0.CO;2-7. [PubMed] [CrossRef] [Google Scholar]

18. Fain O, Pariés J, Jacquart B, et al. Hypovitaminosis C in hospitalized patients. Eur J Intern Med. 2003;14:419–25. doi: 10.1016/j.ejim.2003.08.006. [PubMed] [CrossRef] [Google Scholar]

19. Gupta A, Bhatt ML, Misra MK. Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev. 2009;2:68–72. doi: 10.4161/oxim.2.2.8160. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Gan R, Eintracht S, Hoffer LJ. Vitamin C deficiency in a university teaching hospital. J Am Coll Nutr. 2008;27:428–33. doi: 10.1080/07315724.2008.10719721. [PubMed] [CrossRef] [Google Scholar]

21. Schorah CJ, Downing C, Piripitsi A, et al. Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr. 1996;63:760–5. doi: 10.1093/ajcn/63.5.760. [PubMed] [CrossRef] [Google Scholar]

22. Anthony HM, Schorah CJ. Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer. 1982;46:354–67. doi: 10.1038/bjc.1982.211. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Fain O. Vitamin C [French] Rev Prat. 2013;63:1091–6. [PubMed] [Google Scholar]

24. Mayne S. Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. J Nutr. 2003;133(suppl 3):933S–40S. doi: 10.1093/jn/133.3.933S. [PubMed] [CrossRef] [Google Scholar]

25. Emri S, Kilickap S, Kadilar C, Halil MG, Akay H, Besler T. Serum levels of alpha-tocopherol, vitamin C, beta-carotene, and retinol in malignant pleural mesothelioma. Asian Pac J Cancer Prev. 2012;13:3025–9. doi: 10.7314/APJCP.2012.13.7.3025. [PubMed] [CrossRef] [Google Scholar]

26. Khanzode SS, Khanzode SD, Dakhale GN. Serum and plasma concentration of oxidant and antioxidants in patients of Helicobacter pylori gastritis and its correlation with gastric cancer. Cancer Lett. 2003;195:27–31. doi: 10.1016/S0304-3835(03)00147-2. [PubMed] [CrossRef] [Google Scholar]

27. Mehdi WA, Zainulabdeen JA, Mehde AA. Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev. 2013;14:3663–7. doi: 10.7314/APJCP.2013.14.6.3663. [PubMed] [CrossRef] [Google Scholar]

28. Romney SL, Basu J, Vermund S, Palan PR, Duttagupta C. Plasma reduced and total ascorbic acid in human uterine cervix dysplasia and cancer. Ann N Y Acad Sci. 1987;498:132–43. doi: 10.1111/j.1749-6632.1987.tb23757.x. [PubMed] [CrossRef] [Google Scholar]

29. Jonas CR, Puckett AB, Jones DP, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000;72:181–9. doi: 10.1093/ajcn/72.1.181. [PubMed] [CrossRef] [Google Scholar]

30. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25:983–90. [PubMed] [Google Scholar]

31. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007;22:7–11. doi: 10.3346/jkms.2007.22.1.7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Carr AC, Vissers MD, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol. 2014;4:283. doi: 10.3389/fonc.2014.00283. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe. 2012;1:49–53. doi: 10.1016/j.pmu.2012.05.008. [CrossRef] [Google Scholar]

34. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189. doi: 10.1186/1479-5876-10-189. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Schectman G, Byrd JC, Gruchow HW. The influence of smoking on vitamin C status in adults. Am J Public Health. 1989;79:158–62. doi: 10.2105/AJPH.79.2.158. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Suh SY, Bae WK, Ahn HY, Choi SE, Jung GC, Yeom CH. Intravenous vitamin C administration reduces fatigue in office workers: a double-blind randomized controlled trial. Nutr J. 2012;11:7. doi: 10.1186/1475-2891-11-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Gropper SA, Smith JL, Carr TP. Advanced Nutrition and Human Metabolism. 7th ed. Boston, MA: Cengage Learning; 2009. [Google Scholar]

38. United States, Department of Health and Human Services, National Institutes of Health, Office of Dietary Supplements (ods) Vitamin C: Fact Sheet for Health professionals [Web resource] Bethesda, MD: ODS; 2017. [Current version available at: https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/; cited 15 November 2017] [Google Scholar]

39. Lachapelle MY, Drouin G. Inactivation dates of the human and guinea pig vitamin C genes. Genetica. 2011;139:199–207. doi: 10.1007/s10709-010-9537-x. [PubMed] [CrossRef] [Google Scholar]

40. Mandl J, Szarka A, Bánhegyi G. Vitamin C: update on physiology and pharmacology. Br J Pharmacol. 2009;157:1097–110. doi: 10.1111/j.1476-5381.2009.00282.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

41. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR, Jr, Wang Y, Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res. 1997;14:1133–9. doi: 10.1023/A:1012186203165. [PubMed] [CrossRef] [Google Scholar]

42. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta. 2012;1826:443–57. [PMC free article] [PubMed] [Google Scholar]

43. Corpe CP, Tu H, Eck P, et al. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest. 2010;120:1069–83. doi: 10.1172/JCI39191. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140:533–7. doi: 10.7326/0003-4819-140-7-200404060-00010. [PubMed] [CrossRef] [Google Scholar]

45. Oreopoulos DG, Lindeman RD, Vanderjagt DJ, Tzamaloukas AH, Bhagavan HN, Garry PJ. Renal excretion of ascorbic acid: effect of age and sex. J Am Coll Nutr. 1993;12:537–42. doi: 10.1080/07315724.1993.10718349. [PubMed] [CrossRef] [Google Scholar]

46. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 1996;93:3704–9. doi: 10.1073/pnas.93.8.3704. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

47. Levine M, Padayatty S, Espey M. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011;2:78–88. doi: 10.3945/an.110.000109. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

48. Benke KK. Modeling ascorbic acid level in plasma and its dependence on absorbed dose. J Aust Coll Nutr Env Med. 1999;18:11–12. [Google Scholar]

49. Hickey DS, Roberts HJ, Cathcart RF. Dynamic flow: a new model for ascorbate. J Orthomol Med. 2005;20:237–44. [Google Scholar]

50. United States, Department of Health and Human Services, National Institutes of Health, National Center for Biotechnology Information (ncbi) PubChem Compound Database: Ascorbic acid [Web resource (CID=54670067)] Bethesda, MD: NCBI; n.d. [Available at: https://pubchem.ncbi.nlm.nih.gov/compound/54670067; cited 12 January 2016] [Google Scholar]

51. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003;22:118–23. doi: 10.1080/07315724.2003.10719284. [PubMed] [CrossRef] [Google Scholar]

52. Friedman GJ, Sherry S, Ralli EP. The mechanism of the excretion of vitamin C by the human kidney at low and normal plasma levels of ascorbic acid. J Clin Invest. 1940;19:685–9. doi: 10.1172/JCI101171. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Spellberg MA, Keeton RW. Excretion of ascorbic acid in relation to saturation and utilization with some diagnostic implications. Arch Intern Med. 1939;63:1095–116. doi: 10.1001/archinte.1939.00180230080006. [CrossRef] [Google Scholar]

54. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008;27:7–19. [PubMed] [Google Scholar]

55. Gałecki P, Szemraj J, Bieşkiewicz M, Florkowski A, Gałecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep. 2009;61:436–47. doi: 10.1016/S1734-1140(09)70084-2. [PubMed] [CrossRef] [Google Scholar]

56. Richardson TI, Ball L, Rosenfeld T. Will an orange a day keep the doctor away? Postgrad Med J. 2002;78:292–4. doi: 10.1136/pmj.78.919.292. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology. 2002;180:121–37. doi: 10.1016/S0300-483X(02)00386-4. [PubMed] [CrossRef] [Google Scholar]

58. Berger MM, Baines M, Raffoul W, et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations. Am J Clin Nutr. 2007;85:1293–300. doi: 10.1093/ajcn/85.5.1293. [PubMed] [CrossRef] [Google Scholar]

59. Pelletier O. Smoking and vitamin C levels in humans. Am J Clin Nutr. 1968;21:1259–67. doi: 10.1093/ajcn/21.11.1259. [PubMed] [CrossRef] [Google Scholar]

60. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87:504–8. doi: 10.1038/clpt.2009.254. [PubMed] [CrossRef] [Google Scholar]

61. Jacob RA, Sotoudeh G. Vitamin C function and status in chronic disease. Nutr Clin Care. 2002;5:66–74. doi: 10.1046/j.1523-5408.2002.00005.x. [PubMed] [CrossRef] [Google Scholar]

62. World Health Organization (who), United Nations High Commissioner for Refugees . Scurvy and its Prevention and Control in Major Emergencies. Geneva, Switzerland: WHO; 1999. [Google Scholar]

63. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7–37. [PubMed] [Google Scholar]

64. Mcmillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–6. doi: 10.1097/MCO.0b013e32832a7902. [PubMed] [CrossRef] [Google Scholar]

65. Mikirova NA, Jackson JA, Riordan NH. The effect of high dose IV vitamin C on plasma antioxidant capacity and level of oxidative stress in cancer patients and healthy subjects. J Orthomol Med. 2007;22:153–60. [Google Scholar]

66. Luo M, Fernandez-Estivariz C, Jones DP, et al. Depletion of plasma antioxidants in surgical intensive care unit patients requiring parenteral feeding: effects of parenteral nutrition with or without alanyl-glutamine dipeptide supplementation. Nutrition. 2008;24:37–44. doi: 10.1016/j.nut.2007.10.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

67. Petroianu A, Alberti LR. Effect of oral supplementation of vitamin C on intestinal anastomotic resistance. Rev Col Bras Cir. 2011;38:54–8. doi: 10.1590/S0100-69912011000100010. [PubMed] [CrossRef] [Google Scholar]

68. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5:e11414. doi: 10.1371/journal.pone.0011414. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

69. Robitaille L, Mamer OA, Miller WH, Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009;58:263–9. doi: 10.1016/j.metabol.2008.09.023. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

70. McAllister CJ, Scowden EB, Dewberry FL, Richman A. Renal failure secondary to massive infusion of vitamin C. JAMA. 1984;252:1684. doi: 10.1001/jama.1984.03350130016019. [PubMed] [CrossRef] [Google Scholar]

71. Canavese C, Petrarulo M, Massarenti P, et al. Long-term, lowdose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis. 2005;45:540–9. doi: 10.1053/j.ajkd.2004.10.025. [PubMed] [CrossRef] [Google Scholar]

72. Shahrbanoo K, Taziki O. Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. Saudi J Kidney Dis Transpl. 2008;19:933–6. [PubMed] [Google Scholar]

73. Jacobs C. Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemodialysis patients. Nat Clin Pract Nephrol. 2006;2:552–3. doi: 10.1038/ncpneph0281. [PubMed] [CrossRef] [Google Scholar]

74. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest. 1998;28:695–700. doi: 10.1046/j.1365-2362.1998.00349.x. [PubMed] [CrossRef] [Google Scholar]

75. Mashour S, Turner JF, Jr, Merrell R. Acute renal failure, oxalosis, and vitamin C supplementation: a case report and review of the literature. Chest. 2000;118:561–3. doi: 10.1378/chest.118.2.561. [PubMed] [CrossRef] [Google Scholar]

76. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol. 1999;10:840–5. [PubMed] [Google Scholar]

77. Gerster H. No contribution of ascorbic acid to renal calcium oxalate stones. Ann Nutr Metab. 1997;41:269–82. doi: 10.1159/000177954. [PubMed] [CrossRef] [Google Scholar]

78. Mehta JB, Singhal SB, Mehta BC. Ascorbic-acid-induced haemolysis in g-6-pd deficiency. Lancet. 1990;336:944. doi: 10.1016/0140-6736(90)92317-B. [PubMed] [CrossRef] [Google Scholar]

79. Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ. 1993;306:841–2. doi: 10.1136/bmj.306.6881.841. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

80. Braunstein EM. Glucose 6-phosphate dehydrogenase deficiency. In: Lichtin AE, editor. Merck Manual: Professional Edition. 19th online ed. Kenilworth, NJ: Merck Sharp and Dohme Corp; 2018. [Available at: http://www.merckmanuals.com/professional/hematology_and_oncology/anemias_caused_by_hemolysis/glucose-6-phosphate_dehydrogenase_g6pd_deficiency.html; cited 8 January 2016] [Google Scholar]

81. Glucose-6-phosphate dehydrogenase deficiency who Working Group. Bull World Health Organ. 1989;67:601–11. [PMC free article] [PubMed] [Google Scholar]

82. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi: 10.1016/j.cell.2011.02.013. [PubMed] [CrossRef] [Google Scholar]

83. Clementz AG, Harris A. Collagen xv: exploring its structure and role within the tumor microenvironment. Mol Cancer Res. 2013;11:1481–6. doi: 10.1158/1541-7786.MCR-12-0662. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

84. Bowie AG, O’Neill LA. Vitamin C inhibits nf-kappa b activation by tnf via the activation of p38 mitogen-activated protein kinase. J Immunol. 2000;165:7180–8. doi: 10.4049/jimmunol.165.12.7180. [PubMed] [CrossRef] [Google Scholar]

85. Cárcamo JM, Pedraza A, Bórquez-Ojeda O, Zhang B, Sanchez R, Golde DW. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IκBα kinase β Mol Cell Biol. 2004;24:6645–52. doi: 10.1128/MCB.24.15.6645-6652.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

86. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008;105:11105–9. doi: 10.1073/pnas.0804226105. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

87. Casciari JJ, Riordan HD, Miranda-Massari JR, Gonzalez MJ. Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. P R Health Sci J. 2005;24:145–50. [PubMed] [Google Scholar]

88. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoural effects. Free Radic Biol Med. 2009;47:32–40. doi: 10.1016/j.freeradbiomed.2009.02.016. [PubMed] [CrossRef] [Google Scholar]

89. Espey MG, Chen P, Chalmers B, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011;50:1610–19. doi: 10.1016/j.freeradbiomed.2011.03.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

90. Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007;104:8749–54. doi: 10.1073/pnas.0702854104. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

91. Wefers H, Sies H. The protection by ascorbate and glutathi-one against microsomal lipid peroxidation is dependent on vitamin E. Eur J Biochem. 1988;174:353–7. doi: 10.1111/j.1432-1033.1988.tb14105.x. [PubMed] [CrossRef] [Google Scholar]

92. Mikirova N, Hunnunghake R, Scimeca RC, et al. High-dose intravenous vitamin C treatment of a child with neurofibromatosis type 1 and optic pathway glioma: a case report. Am J Case Rep. 2016;17:774–81. doi: 10.12659/AJCR.899754. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

93. Fritz H, Flower G, Weeks L, et al. Intravenous vitamin C and cancer: a systematic review. Integr Cancer Ther. 2014;13:280–300. doi: 10.1177/1534735414534463. [PubMed] [CrossRef] [Google Scholar]

94. Mastrangelo, D. et al. Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation. Blood Cells. Mol. Dis. 69, 57–64 (2018).

95. Ang, A. et al. Vitamin C and immune cell function in inflammation and cancer. Biochem. Soc. Trans. 46, 1147–1159 (2018).

96. Zhao, H. et al. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk. Res. 66, 1–7 (2018).

97. Mustafi, S. et al. Vitamin C sensitizes melanoma to BET inhibitors. Cancer Res. 78, 572–583 (2018).

98. Klimant, E. et al. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr. Oncol. 25, 139–148 (2018).

99. Wilkes, J. G. et al. Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma. Clin. Exp. Metastasis 35, 37–51 (2018).

100. Vissers, M. C. M. & Das, A. B. Potential mechanisms of action for vitamin C in cancer: reviewing the evidence

 

1 則留言: